Zenith Capital (Zenith Capital) Gross-Profit-to-Asset % : 0.00% (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Zenith Capital's annualized Gross Profit for the quarter that ended in . 20 was $ Mil. Zenith Capital's average Total Assets over the quarter that ended in . 20 was $ 0 Mil. Therefore, Zenith Capital's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 was Not Available.

Zenith Capital Gross-Profit-to-Asset % Historical Data

The historical data trend for Zenith Capital's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Gross-Profit-to-Asset % Chart

Zenith Capital Annual Data

Trend

Gross-Profit-to-Asset %

Zenith Capital Quarterly Data

Gross-Profit-to-Asset %

Competitive Comparison of Zenith Capital's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Zenith Capital's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Gross-Profit-to-Asset % falls into.

Zenith Capital Gross-Profit-to-Asset % Calculation

Zenith Capital's annualized Gross-Profit-to-Asset % for the fiscal year that ended in . 20 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: . 20 )	/	( (Total Assets (A: . 20 )	+	Total Assets (A: . 20 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

Zenith Capital's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: . 20 )	/	( (Total Assets (Q: . 20 )	+	Total Assets (Q: . 20 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (. 20) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Zenith Capital Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines